JOHN POWER KANE
Pilots at Marlborough Rd, Burlingame, CA
License number
California A4020465
Issued Date
Jul 2015
Expiration Date
Jul 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
1490 Marlborough Rd, Burlingame, CA 94010
Professional information
Mature Apoai Protein Production Under Serum Free Culturing Conditions
US Patent:
4943527, Jul 24, 1990
Filed:
Feb 27, 1986
Appl. No.:
6/834300
Inventors:
Andrew A. Protter - Palo Alto CA
Jean-Louis Vigne - San Francisco CA
Joanne B. Mallory - San Jose CA
Karen D. Talmadge - Palo Alto CA
John P. Kane - Hillsborough CA
Jean-Louis Vigne - San Francisco CA
Joanne B. Mallory - San Jose CA
Karen D. Talmadge - Palo Alto CA
John P. Kane - Hillsborough CA
Assignee:
California Biotechnology Inc. - Mountain View CA
International Classification:
C12P 2105, C12P 2102, C12N 1500
US Classification:
435 696
Abstract:
A method of producing a purified lipid-binding peptide which can bind to phospholipids at one or more amphipatic alpha-helical peptide regions. The method includes providing a gene coding for the peptide, and introducing the gene in expressible, heterologous form in a suitable expression system capable of synthesizing a mixture of peptides which includes the lipid-binding peptide. Addition of either endogenous or exogenous lipids to the peptide mixture forms a low-density lipopeptide complex composed of lipid and the lipid-binding peptide, and this complex can be separated easily from nonlipid-binding peptides in the peptide on the basis of its size and/or density. The method is intended particularly for scaled-up production of purified human apolipoproteins and their alpha-helical lipid-binding regions. Also disclosed are related methods for producing recombinant apolipoproteins, therapeutic lipopeptide compositions, and a stabilized lipid emulsion for nutritional therapy. Further disclosed are methods for expressing apolipoproteins or lipid-binding segments thereof in bacterial, yeast and mammalian cell expression systems, and methods for purifying lipid binding proteins, including fused recombinant proteins.
Treatments For Age-Related Macular Degeneration (Amd)
US Patent:
2003022, Dec 11, 2003
Filed:
May 2, 2003
Appl. No.:
10/428551
Inventors:
Daniel Schwartz - San Francisco CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - Hillsborough CA, US
Brian Ishida - Walnut Creek CA, US
Keith Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John Kane - Hillsborough CA, US
Brian Ishida - Walnut Creek CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K031/58, A61K031/56, A61K031/203, A61K031/198
US Classification:
514/177000, 514/559000, 514/567000, 514/172000
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
Methods To Increase Reverse Cholesterol Transport In The Retinal Pigment Epithelium (Rpe) And Bruch's Membrane (Bm)
US Patent:
7470659, Dec 30, 2008
Filed:
Mar 5, 2004
Appl. No.:
10/794198
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/02, A61K 38/17, A61K 31/685
US Classification:
514 2, 514 12, 514 13, 514 21, 514 78
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
Treatment For Dark Adaptation
US Patent:
2010004, Feb 25, 2010
Filed:
Oct 6, 2008
Appl. No.:
12/245944
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Keith G. Duncan - San Francisco CA, US
Kathy R. Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
International Classification:
A61K 9/127, A61K 38/17, A61P 27/02
US Classification:
424450, 514 12
Abstract:
The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
Pharmaceutical Microemulsions
US Patent:
5023271, Jun 11, 1991
Filed:
Aug 13, 1985
Appl. No.:
6/765359
Inventors:
Jean-Louis Vigne - San Francisco CA
John P. Kane - Hillsborough CA
John P. Kane - Hillsborough CA
Assignee:
California Biotechnology Inc. - Mountain View CA
International Classification:
A61K 31355, A61K 31595, A61K 3107, A61K 31225
US Classification:
514458
Abstract:
A method for parenteral administration of fat-soluble pharmaceuticals and vitamins using microemulsions is disclosed. The microemulsions are comprised of a naturally occurring amphipatic substance and a hydrophobic lipid along with the active ingredient, are size selected for 300-1000. ANG. pseudomicelles, and permit safe intravenous injection of the active ingredient. Levels of the active ingredient in the various lipoprotein fractions of serum appear to mimic the natural distribution of the administered drug if taken orally.
Treatment For Dark Adaptation
US Patent:
7470660, Dec 30, 2008
Filed:
Feb 10, 2005
Appl. No.:
11/055309
Inventors:
Daniel M. Schwartz - San Francisco CA, US
Keith G. Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Keith G. Duncan - San Francisco CA, US
Kathy Bailey - San Francisco CA, US
John P. Kane - Hillsborough CA, US
Brian Y. Ishida - Walnut Creek CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/685, A61K 31/7088, A61K 38/02, A61K 38/10, A61K 38/17
US Classification:
514 2, 514 12, 514 13, 514 21, 514 44, 514 78
Abstract:
The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.